Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services... see more

NDAQ:VMD - Post Discussion

Viemed Healthcare Inc > APR was acquired for 7x adj. EBITDA, VMD at 4.5x adj. EBITDA
View:
Post by stockfy on Feb 18, 2022 12:26pm

APR was acquired for 7x adj. EBITDA, VMD at 4.5x adj. EBITDA

VMD's main competitors are Lincare (owned by Linde AG) and Apria Healthcare (APR).
 
APR's top line YoY growth this year is only 4%, see:

https://www.globenewswire.com/news-release/2021/11/04/2328043/4031/en/Apria-Announces-Financial-Results-for-Third-Quarter-2021.html
 
 
For comparison, VMD's top line YoY growth for its core business this year is 12%:
 
 "Net revenues attributable to the Company's core business for the quarter ended September 30, 2021 were $27.8 million, a new Company record, and an increase of $2.9 million, or 12%, over core business revenues reported for the comparable quarter ended September 30, 2020."
 
 
APR was acquired just one month ago for a total transaction value of $1.6 billion:

https://www.pymnts.com/acquisitions/2022/healthcare-firm-owens-minor-buys-apria-for-1-6b/

 
According to APR's guidance, adj. EBITDA this year is about $230 million.
 
Therefore, APR with only 4% YoY growth was acquired for 7 times its adj. EBITDA.

 
For comparison, VMD's adj. EBITDA this year will be about $28-$29 million.

VMD's Enterprise Value at US$4 per share is $140 million.

Therefore, VMD has 12% YoY growth (VMD reports much stronger growth than APR) but its Enterprise Value at US$4 per share is only 4.5 times its adj. EBITDA!!!

 
Comment by LongTerm3 on Feb 18, 2022 1:47pm
APR expected Adjusted EPS growth is 8 percent next year. Viemed expected Adjusted EPS growth is over 20 percent next year. APR also has debt of over 400 Million. Viemed debt is about 4 Million.    APR has 100 times the debt. That is huge. That is why they were about to get the company at only 7 times ADJ. EBITA. Viemed would go for more.  APR has about 35 million shares ...more  
Comment by donmayne on Feb 18, 2022 2:14pm
At the Stifel CC (Nov 16, 2021), the Moderator asked about the big picture post covid which we hope is not in the too distant future. If we are in a steady state  how should we think about Viemed's top line and margin profile. Casey Hoyt responded where he said we are never satisfied unless we grow north of 30%.  We are used to growing at 30-40% range. We grew the core business ...more  
Comment by LongTerm3 on Feb 18, 2022 2:57pm
Please start a new text if changing the subject. Covid has come down dramatically in the last month.
Comment by donmayne on Feb 19, 2022 1:44pm
Sorry Longterm...I thought the conversation was about growth rates so I posted the most recent public observation from Casey Hoyt and commented that it would have to be adjusted downwards for the subsequent Omicron surge.  I felt that was the same subject of growth rates that you were speaking to.   Since posting my comments, I have now read Stockfy's vitriolic attack on an ...more  
Comment by stockfy on Feb 19, 2022 5:33am
Good catch in terms of debt/leverage. APR was a leveraged (indebted) company with its leverage being about 2 times. In contrast, VMD has a fortress balance sheet with a net cash position. To sum it up: 1) VMD's top line YoY growth is much stronger than APR's and 2) VMD has a net cash position of about $20 million while APR was an indebted company with its leverage being about 2 times. ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities